{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-144174","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.236852+00:00","generated_at":"2026-05-18T23:30:43.139590+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating","bullets":["Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).","CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).","Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).","No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.","Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-144174","json":"https://secwatch.observer/filing/0001193125-25-144174.json","markdown":"https://secwatch.observer/filing/0001193125-25-144174.md","text":"https://secwatch.observer/filing/0001193125-25-144174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/0001193125-25-144174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/d874957d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:30:43.139590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}